Oberhausen
Oberhausen
Oberhausen, Germany5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis | Skin and Connective Tissue Diseases, connective tissue disorder, skin disorder, systemic sclerosis | Recruiting | Phase 3 | 2026-09-30 | NCT07497087 | |
| International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Gaucher disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, nervous system disorder, sphingolipidosis | Recruiting | Not stated | 2026-04-14 | NCT00358943 | |
| Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients | Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, basal cell carcinoma, basal cell neoplasm, carcinoma, epithelial neoplasm, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-03-11 | NCT06981325 | |
| Therapy Optimisation for the Treatment of Hairy Cell Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hairy cell leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 / Phase 3 | 2024-08-22 | NCT02131753 | |
| Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions | Hemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 2 | 2024-01-31 | NCT05384691 |